Onkologische Schwerpunktpraxis - Leer
About Onkologische Schwerpunktpraxis - Leer
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
German CLL Study Group
5
European Organisation for Research and Treatment of Cancer - EORTC
3
Hoffmann-La Roche
3
Celgene
1
German High-Grade Non-Hodgkin's Lymphoma Study Group
1
Heidelberg University
1
III. Medizinische Klinik Mannheim
1
Mologen AG
1
NSABP Foundation Inc
1
Pfizer
1
PharmaMar
1
Clinical Trials at Onkologische Schwerpunktpraxis - Leer
During the past decade, Onkologische Schwerpunktpraxis - Leer conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on
average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
1997-07-01
Unknown status
1,000
Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
2002-05-01
Unknown status
220
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
2002-06-01
2017-03-31
Completed
1,551
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
2003-05-01
Completed
86
Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
2003-07-01
Terminated
88
Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
1997-04-01
2010-06-01
Completed
877
Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia
2005-11-01
2011-03-01
Completed
195
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
2005-10-01
2015-06-01
Completed
825
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis - Leer" #1 sponsor was "German CLL Study Group" with 5 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials
sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Celgene" with 1 trials sponsored and "German High-Grade Non-Hodgkin's Lymphoma Study Group"
with 1 trials sponsored. Other sponsors include 7 different institutions and
companies that sponsored additional 17 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis - Leer"
#1 collaborator was "German CLL Study Group" with 2 trials as a collaborator, "GlaxoSmithKline" with 2 trials as a collaborator, "Arbeitsgemeinschaft fur Internistische Onkologie" with 1 trials as a collaborator, "Arbeitskreis Klinische Studien" with 1 trials as a collaborator and "Cancer International Research Group (CIRG)" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were
collaborators in the rest 14 trials.
Clinical Trials Conditions at Onkologische Schwerpunktpraxis - Leer
According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis - Leer" are
"Chronic Lymphocytic Leukemia" (6 trials), "Leukemia" (4 trials), "Advanced/Metastatic Breast Cancer" (1 trials), "Anal Cancer" (1 trials) and "Anemia" (1 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis - Leer" in a lesser frequency.
Clinical Trials Intervention Types at Onkologische Schwerpunktpraxis - Leer
Most popular intervention types in "Onkologische Schwerpunktpraxis - Leer" are "Drug" (23 trials), "Biological" (6 trials), "Procedure" (3 trials), "Radiation" (3 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Rituximab" (4 trials), "Cyclophosphamide" (3 trials), "Fludarabine" (3 trials), "Placebo" (3 trials) and "radiation therapy" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Onkologische Schwerpunktpraxis - Leer
The vast majority of trials in "Onkologische Schwerpunktpraxis - Leer" are
23 trials for "All" genders and 2 trials for "Female" genders.
Clinical Trials Status at Onkologische Schwerpunktpraxis - Leer
Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis - Leer".
undefined are not yet recruiting,
1 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 14 completed trials in Onkologische Schwerpunktpraxis - Leer,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Onkologische Schwerpunktpraxis - Leer, 2 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 19 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".